Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies.
Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies.
复制标题
DOI：
10.1016/j.expneurol.2020.113518
复制
发表时间：
2021-01
影响因子：
5.3
通讯作者：
Candelario-Jalil E
中科院分区：
文献类型：
--
作者：
Paul S;Candelario-Jalil E
中风是导致残疾的主要原因，也是全球第二大死亡原因。随着全球65岁及以上人口的增长速度超过所有其他年龄组，中风的发病率也在增加。此外，总体中风负担向较年轻的年龄组转移，特别是在低收入和中等收入国家。在大多数情况下，中风是由于动脉的突然阻塞引起的（缺血性中风），但在一些情况下，中风可能是由于血管破裂时出血进入脑组织引起的（出血性中风）。虽然卒中的治疗选择仍然有限，但随着药物和机械溶栓再通治疗的进步，在帮助患者从缺血性卒中中恢复方面取得了一些进展。然而，仍然需要开发用于急性缺血性卒中的神经保护的治疗剂，以保护脑在再通之前和再通期间免受损伤，延长介入治疗的时间窗并进一步改善功能结局。本文综述了神经保护剂的研究进展、临床研究进展、美国国家神经疾病和卒中研究所（National Institute of Neurological Disorders and Stroke，SPAN）在寻找新型神经保护剂方面的最新进展，以及目前正在临床前研究中评价的新型神经保护剂。每一种神经保护策略的潜在分子机制也已被总结，这可能有助于未来的联合治疗中风治疗策略的发展。
Stroke is the leading cause of disability and the second leading cause of death worldwide. With the global population aged 65 and over growing faster than all other age groups, the incidence of stroke is also increasing. In addition, there is a shift in the overall stroke burden towards younger age groups, particularly in low and middle-income countries. Stroke in most cases is caused due to an abrupt blockage of an artery (ischemic stroke), but in some instances stroke may be caused due to bleeding into brain tissue when a blood vessel ruptures (hemorrhagic stroke). Although treatment options for stroke are still limited, with the advancement in recanalization therapy using both pharmacological and mechanical thrombolysis some progress has been made in helping patients recover from ischemic stroke. However, there is still a substantial need for the development of therapeutic agents for neuroprotection in acute ischemic stroke to protect the brain from damage prior to and during recanalization, extend the therapeutic time window for intervention and further improve functional outcome. The current review has assessed the past challenges in developing neuroprotective strategies, evaluated the recent advances in clinical trials, discussed the recent initiative by the National Institute of Neurological Disorders and Stroke in USA for the search of novel neuroprotectants (Stroke Preclinical Assessment Network, SPAN) and identified emerging neuroprotectants being currently evaluated in preclinical studies. The underlying molecular mechanism of each of the neuroprotective strategies have also been summarized, which could assist in the development of future strategies for combinational therapy in stroke treatment.
登录
查看更多内容
DOI：
10.4049/jimmunol.1202496
发表时间：
2013-06-15
期刊：
Journal of immunology (Baltimore, Md. : 1950)
影响因子：
--
作者：
Banerjee S;Xie N;Cui H;Tan Z;Yang S;Icyuz M;Abraham E;Liu G
通讯作者：
Liu G
影响因子：
6
作者：
Bedi, Supinder S.;Hetz, Robert;Cox, Charles S., Jr.
通讯作者：
Cox, Charles S., Jr.
影响因子：
3.3
作者：
Aliena-Valero, Alicia;Lopez-Morales, Mikahela A.;Salom, Juan B.
通讯作者：
Salom, Juan B.
影响因子：
4.3
作者：
Aydin, Suleyman;Kuloglu, Tuncay;Kendir, Yalcin
通讯作者：
Kendir, Yalcin
影响因子：
8.3
作者：
Amin-Hanjani, S;Stagliano, NE;Moskowitz, MA
通讯作者：
Moskowitz, MA